1 

UNITED STATES OF AMERICA

BEFORE THE FEDERAL TRADE COMMISSION

In the Matter of

BASF SE, a corporation, 

BASF CORPORATION, a corporation, and 

DIEM LABS, LLC, a limited liability company,

et al. 

FILE NO. 192-3088 

AGREEMENT CONTAINING 

CONSENT ORDER WITH 

RESPONDENTS BASF SE AND 

BASF CORPORATION

 The Federal Trade Commission (“Commission”) has conducted an investigation of 

certain acts and practices of BASF SE and BASF Corporation (collectively “Proposed 

Respondents”). The Commission’s Bureau of Consumer Protection (“BCP”) has prepared a 

draft of an administrative Complaint (“draft Complaint”). BCP and Proposed Respondents, 

through their duly authorized officers, enter into this Agreement Containing Consent Order 

(“Consent Agreement”) to resolve the allegations in the attached draft Complaint through a 

proposed Decision and Order to present to the Commission, which is also attached and made a 

part of this Consent Agreement. 

IT IS HEREBY AGREED by and between BASF SE and BASF Corporation and BCP 

that:

1. The Proposed Respondents are:

a. BASF SE, multi-national corporation based in Ludwigshafen, Germany, and

b. BASF Corporation, a Delaware corporation with offices at 100 Park Avenue, Florham

Park, New Jersey 07932.

2. Proposed Respondents neither admit nor deny any of the allegations in the Complaint, except

as specifically stated in the Decision and Order. Only for purposes of this action, Proposed

Respondents admit the facts necessary to establish jurisdiction.

3. Proposed Respondents waive:

a. any further procedural steps;

b. the requirement that the Commission’s Decision contain a statement of findings of
2 

fact and conclusions of law; and

c. all rights to seek judicial review or otherwise to challenge or contest the validity of

the Decision and Order issued pursuant to this Consent Agreement.

4. This Consent Agreement will not become part of the public record of the proceeding unless

and until it is accepted by the Commission. If the Commission accepts this Consent

Agreement, it, together with the draft Complaint, will be placed on the public record for 30

days and information about them publicly released. Acceptance does not constitute final

approval, but it serves as the basis for further actions leading to final disposition of the

matter. Thereafter, the Commission may either withdraw its acceptance of this Consent

Agreement and so notify Proposed Respondents, in which event the Commission will take

such action as it may consider appropriate, or issue and serve its Complaint (in such form as

the circumstances may require) and decision in disposition of the proceeding, which may

include an Order. See Section 2.34 of the Commission’s Rules, 16 C.F.R. § 2.34 (“Rule

2.34”).

5. If this agreement is accepted by the Commission, and if such acceptance is not subsequently

withdrawn by the Commission pursuant to Rule 2.34, the Commission may, without further

notice to Proposed Respondents: (1) issue its Complaint corresponding in form and

substance with the attached draft Complaint and its Decision and Order; and (2) make

information about them public. Proposed Respondents agree that service of the Order may

be effected by its publication on the Commission’s website (ftc.gov), at which time the Order

will become final. See Rule 2.32(d). Proposed Respondent waives any rights it may have to

any other manner of service. See Rule 4.4.

6. When final, the Decision and Order will have the same force and effect and may be altered,

modified, or set aside in the same manner and within the same time provided by statute for

other Commission orders.

7. The Complaint may be used in construing the terms of the Decision and Order. No

agreement, understanding, representation, or interpretation not contained in the Decision and

Order or in this Consent Agreement may be used to vary or contradict the terms of the

Decision and Order.
3 

8. Proposed Respondents agree to comply with the terms of the proposed Decision and Order

from the date that Proposed Respondents sign this Consent Agreement. Proposed

Respondents understand that they may be liable for civil penalties and other relief for each

violation of the Decision and Order after it becomes final.

FEDERAL TRADE COMMISSION

_______________________________Date: _________ 

By: Janet Evans

Attorney

Bureau of Consumer Protection 

APPROVED: 

_______________________________Date: _________ 

Serena Viswanathan

Acting Associate Director

Division of Advertising Practices

_______________________________Date: _________ 

Daniel Kaufman

Acting Director

Bureau of Consumer Protection 

BASF SE

______________________________Date: __________ 

By: Julia Raquet, 

Senior Vice President,

Animal Nutrition & Aroma Ingredients

BASF Corporation

______________________________Date: __________ 

By: Stefan John 

Senior Vice President, General Counsel and Chief 

Compliance Officer 

s/ Janet Evans

 s/ Serena Viswanathan

/s/Daniel Kaufman/LEF 2/16/2021
4 

______________________________ Date: __________ 

By: Kathleen M. Sanzo, Esq. 

Morgan, Lewis & Bockius LLP 

Attorney for BASF SE and BASF Corporation 

______________________________ Date: __________ 

By: Willard K. Tom, Esq. 

Morgan, Lewis & Bockius LLP 

Attorney for BASF SE and BASF Corporation 
5 

COMMISSIONERS: Rebecca Kelly Slaughter, Acting Chairwoman

Noah Joshua Phillips 

Rohit Chopra 

Christine S. Wilson 

In the Matter of

BASF SE, a corporation, 

BASF CORPORATION, a corporation, and 

DIEM LABS, LLC, a limited liability company, 

et al. 

DOCKET NO. 

DECISION

The Federal Trade Commission (“Commission”) initiated an investigation of certain acts and 

practices of the Respondents named in the caption. The Commission’s Bureau of Consumer 

Protection (“BCP”) prepared and furnished to Respondents a draft Complaint. BCP proposed to 

present the draft Complaint to the Commission for its consideration. If issued by the 

Commission, the draft Complaint would charge the Respondents with violations of the Federal 

Trade Commission Act.

Respondents and BCP thereafter executed an Agreement Containing Consent Order 

(“Consent Agreement”). The Consent Agreement includes: 1) statements by Respondents that 

they neither admit nor deny any of the allegations in the Complaint, except as specifically stated 

in this Decision and Order, and that only for purposes of this action, they admit the facts 

necessary to establish jurisdiction; and 2) waivers and other provisions as required by the 

Commission’s Rules.

The Commission considered the matter and determined that it had reason to believe that 

Respondents have violated the Federal Trade Commission Act, and that a Complaint should 

issue stating its charges in that respect. The Commission accepted the executed Consent 

Agreement and placed it on the public record for a period of 30 days for the receipt and 

consideration of public comments. The Commission duly considered any comments received 

from interested persons pursuant to Section 2.34 of its Rules, 16 C.F.R. § 2.34. Now, in further 

conformity with the procedure prescribed in Rule 2.34, the Commission issues its Complaint, 

makes the following Findings, and issues the following Order: 
6 

Findings

1. The Proposed Respondents are:

a. BASF SE, multi-national corporation based in Ludwigshafen, Germany, and

b. BASF Corporation, a Delaware corporation with offices at 100 Park Avenue,

Florham Park, New Jersey 07932.

2. The Commission has jurisdiction over the subject matter of this proceeding and over the

Respondents, and the proceeding is in the public interest.

ORDER

Definitions

For the purpose of this Order, the following definitions apply: 

A. “Covered Product” means Hepaxa, Hepaxa PD, and any other Dietary Supplement,

Food, or Drug that contains one or more Omega-3 fatty acids or is promoted by a Respondent or

its subsidiary to benefit cardiac, metabolic, or hepatic health or functions, including the

prevention, mitigation, treatment, or cure of any disease of such systems.

B. “Dietary Supplement” means: (1) any product labeled as a Dietary Supplement or

otherwise represented as a Dietary Supplement; or (2) any pill, tablet, capsule, powder, softgel,

gelcap, liquid, or other similar form containing one or more ingredients that are a vitamin,

mineral, herb or other botanical, amino acid, probiotic, or other dietary substance for use by

humans to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite,

constituent, extract, or combination of any ingredient described above, that is intended to be

ingested, and is not represented to be used as a conventional food or as a sole item of a meal or

the diet.

C. “Drug” means: (1) articles recognized in the official United States Pharmacopoeia,

official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or

any supplement to any of them; (2) articles intended for use in the diagnosis, cure, mitigation,

treatment, or prevention of disease in humans; (3) articles (other than Food) intended to affect

the structure or any function of the body of humans; and (4) articles intended for use as a

component of any article specified in (1), (2), or (3); but does not include devices or their

components, parts, or accessories.

D. “Essentially Equivalent Product” means a product that contains the identical

ingredients, except for inactive ingredients (e.g., binders, colors, fillers, excipients) in the same

form and dosage, and with the same route of administration (e.g., orally, sublingually), as the

Covered Product; provided that the Covered Product may contain additional ingredients if

reliable scientific evidence generally accepted by experts in the field indicates that the amount
7 

and combination of additional ingredients is unlikely to impede or inhibit the effectiveness of the 

ingredients in the Essentially Equivalent Product. 

E. “Food” means: (1) any article used for Food or drink for humans; (2) chewing gum; and

(3) any article used for components of any such article.

F. “Respondents” means BASF SE, and its successors and assigns, and BASF Corporation,

and its successors and assigns.

Provisions 

I. Prohibited Representations: Regarding Health-Related Claims Requiring

Human Clinical Testing for Substantiation

IT IS ORDERED that Respondents, Respondents’ officers, agents, employees, and 

attorneys, and all other persons in active concert or participation with any of them, who receive 

actual notice of this Order, whether acting directly or indirectly, in connection with the labeling, 

advertising, promotion, offering for sale, sale, or distribution of any Covered Product, must not 

make, expressly or by implication, including through the use of a product or program name, 

endorsement, depiction, or illustration, any representation that such product reduces liver fat in 

adults or children with Non-alcoholic Fatty Liver Disease (NAFLD), or cures, mitigates, or treats 

any disease, including but not limited to liver disease, unless the representation is nonmisleading, and, at the time of making such representation, they possess and rely upon 

competent and reliable scientific evidence substantiating that the representation is true. For 

purposes of this Provision, competent and reliable scientific evidence must consist of human 

clinical testing of the Covered Product, or of an Essentially Equivalent Product, that is sufficient 

in quality and quantity based on standards generally accepted by experts in the relevant disease, 

condition, or function to which the representation relates, when considered in light of the entire 

body of relevant and reliable scientific evidence, to substantiate that the representation is true. 

Such testing must be: (1) randomized, double-blind, and placebo-controlled; and (2) conducted 

by researchers qualified by training and experience to conduct such testing. In addition, all 

underlying or supporting data and documents generally accepted by experts in the field as 

relevant to an assessment of such testing as described in the Provision entitled Preservation of 

Records Relating to Competent and Reliable Human Clinical Tests or Studies must be available 

for inspection and production to the Commission. Persons covered by this Provision have the 

burden of proving that a product satisfies the definition of Essentially Equivalent Product. 

II. Prohibited Claims: Other Health-Related Claims

IT IS FURTHER ORDERED that Respondents, Respondents’ officers, agents, 

employees, and attorneys, and all other persons in active concert or participation with any of 

them, who receive actual notice of this Order, whether acting directly or indirectly, in connection 

with the labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered 

Product, must not make, expressly or by implication, including through the use of a product or 

program name, endorsement, depiction, or illustration, any representation, other than 

representations covered under the Provision of this Order entitled Prohibited Representations: 
8 

Regarding Health-Related Claims Requiring Human Clinical Testing for Substantiation, about 

the health benefits, performance, efficacy, safety, or side effects of any Covered Product, unless 

the representation is non-misleading, and, at the time of making such representation, they possess 

and rely upon competent and reliable scientific evidence that is sufficient in quality and quantity 

based on standards generally accepted by experts in the relevant disease, condition, or function to 

which the representation relates, when considered in light of the entire body of relevant and 

reliable scientific evidence, to substantiate that the representation is true. 

For purposes of this Provision, competent and reliable scientific evidence means tests, 

analyses, research, or studies (1) that have been conducted and evaluated in an objective manner 

by experts in the relevant disease, condition, or function to which the representation relates; (2) 

that are generally accepted by such experts to yield accurate and reliable results; and (3) that are 

randomized, double-blind, and placebo-controlled human clinical testing of the Covered Product, 

or of an Essentially Equivalent Product, when such experts would generally require such human 

clinical testing to substantiate that the representation is true. In addition, when such tests or 

studies are human clinical tests or studies, all underlying or supporting data and documents 

generally accepted by experts in the field as relevant to an assessment of such testing as set forth 

in the Provision entitled Preservation of Records Relating to Competent and Reliable Human 

Clinical Tests or Studies must be available for inspection and production to the Commission. 

Persons covered by this Provision have the burden of proving that a product satisfies the 

definition of Essentially Equivalent Product. 

III. Prohibited Misrepresentations Regarding Tests, Studies, or Other Research

IT IS FURTHER ORDERED that Respondents, Respondents’ officers, agents, 

employees, and attorneys, and all other persons in active concert or participation with any of 

them, who receive actual notice of this Order, whether acting directly or indirectly, in connection 

with the labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered 

Product, must not misrepresent, in any manner, expressly or by implication, including through 

the use of any product or program name, endorsement, depiction, or illustration: 

A. that any Covered Product is clinically proven to reduce liver fat in adults or

children with NAFLD;

B. that any Covered Product is clinically proven to cure, mitigate, or treat any

disease;

C. that the health benefits, performance, or safety of any Covered Product is

scientifically or clinically proven or otherwise established; or

D. the existence, contents, validity, results, conclusions, or interpretations of any test,

study, or research relating to the health benefits, performance, safety, or side

effects of any Covered Product.
9 

IV. FDA-Approved Claims

IT IS FURTHER ORDERED that nothing in this Order prohibits Respondents, 

Respondents’ officers, agents, employees, and attorneys, or all other persons in active concert or 

participation with any of them from:

A. for any Drug, making a representation that is approved in labeling for such Drug

under any tentative final or final monograph promulgated by the Food and Drug

Administration, or under any new Drug application approved by the Food and

Drug Administration; and

B. for any product, making a representation that is specifically authorized for use in

labeling for such product by regulations promulgated by the Food and Drug

Administration pursuant to the Nutrition Labeling and Education Act of 1990 or

permitted under Sections 303-304 of the Food and Drug Administration

Modernization Act of 1997.

V. Preservation of Records Relating to Competent and Reliable

Human Clinical Tests or Studies

IT IS FURTHER ORDERED that, with regard to any human clinical test or study 

(“test”) upon which Respondents rely to substantiate any claim covered by this Order, 

Respondents must secure and preserve all underlying or supporting data and documents 

generally accepted by experts in the field as relevant to an assessment of the test, including:

A. all protocols and protocol amendments, reports, articles, write-ups, or other

accounts of the results of the test, and drafts of such documents reviewed by the

test sponsor or any other person not employed by the research entity;

B. all documents referring or relating to recruitment; randomization; instructions,

including oral instructions, to participants; and participant compliance;

C. documents sufficient to identify all test participants, including any participants

who did not complete the test, and all communications with any participants

relating to the test; all raw data collected from participants enrolled in the test,

including any participants who did not complete the test; source documents for

such data; any data dictionaries; and any case report forms;

D. all documents referring or relating to any statistical analysis of any test data,

including any pretest analysis, intent-to-treat analysis, or between-group analysis

performed on any test data; and

E. all documents referring or relating to the sponsorship of the test, including all

communications and contracts between any sponsor and the test’s researchers.
10

Provided, however, the preceding preservation requirement does not apply to a reliably reported 

test, unless the test was conducted, controlled, or sponsored, in whole or in part, by: (1) the 

Respondent; (2) the Respondent’s officers, agents, representatives, or employees; (3) any other 

person or entity in active concert or participation with the Respondent; (4) any person or entity 

affiliated with or acting on behalf of the Respondent; (5) any supplier of any ingredient 

contained in the product at issue to any of the foregoing or to the product’s manufacturer; or (6) 

the supplier or manufacturer of such product. 

For purposes of this Provision, “reliably reported test” means a report of the test has been 

published in a peer-reviewed journal, and such published report provides sufficient information 

about the test for experts in the relevant field to assess the reliability of the results.

For any test conducted, controlled, or sponsored, in whole or in part, by the Respondent, the 

Respondent must establish and maintain reasonable procedures to protect the confidentiality, 

security, and integrity of any personal information collected from or about participants. These 

procedures must be documented in writing and must contain administrative, technical, and 

physical safeguards appropriate to the Respondent’s size and complexity, the nature and scope of 

the Respondent’s activities, and the sensitivity of the personal information collected from or 

about the participants. 

VI. Monetary Relief

IT IS FURTHER ORDERED that:

A. Respondents must pay to the Commission $259,596, which Respondents stipulate

their designated agent, Wilmington Trust, holds in escrow for no purpose other than

payment to the Commission.

B. Such payment must be made within 8 days of the effective date of this Order by

electronic fund transfer in accordance with instructions provided by a representative of

the Commission.

VII. Additional Monetary Provisions

IT IS FURTHER ORDERED that:

A. Respondents relinquish dominion and all legal and equitable right, title, and

interest in all assets transferred pursuant to this Order and may not seek the return of any

assets.

B. The facts alleged in the Complaint will be taken as true, without further proof, in

any subsequent civil litigation by or on behalf of the Commission, including in a

proceeding to enforce its rights to any payment or monetary judgment pursuant to this

Order, such as a nondischargeability complaint in any bankruptcy case.

C. The facts alleged in the Complaint establish all elements necessary to sustain an

action by the Commission pursuant to Section 523(a)(2)(A) of the Bankruptcy Code, 11
11

U.S.C. § 523(a)(2)(A), and this Order will have collateral estoppel effect for such 

purposes.

D. All money paid to the Commission pursuant to this Order may be deposited into a 

fund administered by the Commission or its designee to be used for relief, including 

consumer redress and any attendant expenses for the administration of any redress fund. 

If a representative of the Commission decides that direct redress to consumers is wholly 

or partially impracticable or money remains after redress is completed, the Commission 

may apply any remaining money for such other relief (including consumer information 

remedies) as it determines to be reasonably related to Respondent’s practices alleged in 

the Complaint. Any money not used is to be deposited to the U.S. Treasury. 

Respondents have no right to challenge any activities pursuant to this Provision.

E. In the event of default on any obligation to make payment under this Order, 

interest, computed as if pursuant to 28 U.S.C. § 1961(a), shall accrue from the date of 

default to the date of payment. In the event such default continues for 10 days beyond 

the date that payment is due, the entire amount will immediately become due and 

payable.

F. Each day of nonpayment is a violation through continuing failure to obey or 

neglect to obey a final order of the Commission and thus will be deemed a separate 

offense and violation for which a civil penalty shall accrue.

G. Respondents acknowledge that their Taxpayer Identification Numbers (Social 

Security or Employer Identification Numbers), which Respondents have previously 

submitted to the Commission, may be used for collecting and reporting on any delinquent 

amount arising out of this Order, in accordance with 31 U.S.C. § 7701.

VIII. Acknowledgments of the Order

IT IS FURTHER ORDERED that Respondents obtain acknowledgments of receipt of 

this Order:

A. Each Respondent, within 10 days after the effective date of this Order, must 

submit to the Commission an acknowledgment of receipt of this Order. 

B. Each Respondent must deliver a copy of this Order to: (1) all principals, officers, 

directors, and LLC managers and members; (2) all employees, agents, and 

representatives having managerial responsibilities for conduct related to the 

subject matter of the Order; and (3) any business entity resulting from any change 

in structure as set forth in the Provision titled Compliance Reports and Notices. 

Delivery must occur within 10 days after the effective date of this Order for 

current personnel. For all others, delivery must occur before they assume their 

responsibilities.
12

C. From each individual or entity to which a Respondent delivered a copy of this

Order, that Respondent must obtain, within 30 days, a signed and dated

acknowledgment of receipt of this Order.

IX. Compliance Reports and Notices

IT IS FURTHER ORDERED that Respondents make timely submissions to the 

Commission: 

A. One year after the issuance date of this Order, each Respondent must submit a

compliance report, sworn under penalty of perjury, in which each Respondent must: (a)

identify the primary physical, postal, and email address and telephone number, as

designated points of contact, which representatives of the Commission, may use to

communicate with Respondent; (b) identify all of that Respondent’s businesses by all of

their names, telephone numbers, and physical, postal, email, and Internet addresses; (c)

describe the activities of each business, including the goods and services offered, the

means of advertising, marketing, and sales, and the involvement of any other Respondent

(which Individual Respondents must describe if they know or should know due to their

own involvement); (d) describe in detail whether and how that Respondent is in

compliance with each Provision of this Order, including a discussion of all of the changes

the Respondent made to comply with the Order; and (e) provide a copy of each

Acknowledgment of the Order obtained pursuant to this Order, unless previously

submitted to the Commission.

B. Each Respondent must submit a compliance notice, sworn under penalty of

perjury, within 14 days of any change in the following: (a) any designated point of

contact; or (b) the structure of any Corporate Respondent or any entity that Respondent

has any ownership interest in or controls directly or indirectly that may affect compliance

obligations arising under this Order, including: creation, merger, sale, or dissolution of

the entity or any subsidiary, parent, or affiliate that engages in any acts or practices

subject to this Order.

C. Each Respondent must submit notice of the filing of any bankruptcy petition,

insolvency proceeding, or similar proceeding by or against such Respondent within 14

days of its filing.

D. Any submission to the Commission required by this Order to be sworn under

penalty of perjury must be true and accurate and comply with 28 U.S.C. § 1746, such as

by concluding: “I declare under penalty of perjury under the laws of the United States of

America that the foregoing is true and correct. Executed on: _____” and supplying the

date, signatory’s full name, title (if applicable), and signature.

E. Unless otherwise directed by a Commission representative in writing, all

submissions to the Commission pursuant to this Order must be emailed to

DEbrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to: Associate

Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission,
13

600 Pennsylvania Avenue NW, Washington, DC 20580. The subject line must begin: In 

re BASF SE.

X. Recordkeeping

IT IS FURTHER ORDERED that Respondents must create certain records for 10 years 

after the issuance date of the Order, and retain each such record for 5 years. Specifically,

Corporate Respondent must create and retain the following records: 

A. accounting records showing the revenues from such product;

B. personnel records showing, for each person providing services in relation to any

aspect of the Order, whether as an employee or otherwise, that person’s: name;

addresses; telephone numbers; job title or position; dates of service; and (if applicable)

the reason for termination;

C. records of all consumer complaints concerning the subject matter of the order and

all refund requests, whether received directly or indirectly, such as through a third party,

and any response;

D. all records necessary to demonstrate full compliance with each provision of this

Order, including all submissions to the Commission;

E. a copy of each unique advertisement or other marketing material making a

representation subject to this Order;

F. for 5 years from the date of the last dissemination of any representation covered

by this Order:

1. all materials that were relied upon in making the representation; and

2. all tests, studies, analysis, demonstrations, other research or other such

evidence in Respondent’s possession, custody, or control that contradicts,

qualifies, or otherwise calls into question the representation, or the basis relied

upon for the representation, including complaints and other communications with

consumers or with governmental or consumer protection organizations.

G. for 5 years from the date received, copies of all subpoenas and other

communications with law enforcement, if such communication relate to Respondents’

compliance with this Order.

H. for 5 years from the date created or received, all records, whether prepared by or

on behalf of Respondents, that demonstrate non-compliance or tend to show any lack of

compliance by Respondents with this Order.
14

XI. Compliance Monitoring

IT IS FURTHER ORDERED that, for the purpose of monitoring Respondents’ 

compliance with this Order: 

A. Within 30 days of receipt of a written request from a representative of the

Commission, each Respondent must: submit additional compliance reports or other

requested information, which must be sworn under penalty of perjury; appear for

depositions; and produce documents for inspection and copying. The Commission is also

authorized to obtain discovery, without further leave of court, using any of the procedures

prescribed by Federal Rules of Civil Procedure 29, 30 (including telephonic depositions),

31, 33, 34, 36, 45, and 69.

B. For matters concerning this Order, the Commission is authorized to communicate

directly with each Respondent. Respondents must permit representatives of the

Commission to interview any employee or other person affiliated with Respondent who

has agreed to such an interview. The person interviewed may have counsel present.

C. The Commission may use all other lawful means, including posing, through its

representatives as consumers, suppliers, or other individuals or entities, to Respondents or

any individual or entity affiliated with Respondents, without the necessity of

identification or prior notice. Nothing in this Order limits the Commission’s lawful use

of compulsory process, pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49,

57b-1.

XII. Order Effective Dates

IT IS FURTHER ORDERED that this Order is final and effective upon the date of its 

publication on the Commission’s website (ftc.gov) as a final order. This Order will terminate 20 

years from the date of its issuance (which date may be stated at the end of this Order, near the 

Commission’s seal), or 20 years from the most recent date that the United States or the 

Commission files a complaint (with or without an accompanying settlement) in federal court 

alleging any violation of this Order, whichever comes later; provided, however, that the filing of 

such a complaint will not affect the duration of:

A. Any Provision in this Order that terminates in less than 20 years;

B. This Order’s application to any Respondent that is not named as a defendant in

such complaint; and

C. This Order if such complaint is filed after the Order has terminated pursuant to

this Provision.

Provided, further, that if such complaint is dismissed or a federal court rules that the Respondent 

did not violate any provision of the Order, and the dismissal or ruling is either not appealed or 

upheld on appeal, then the Order will terminate according to this Provision as though the 
15

complaint had never been filed, except that the Order will not terminate between the date such 

complaint is filed and the later of the deadline for appealing such dismissal or ruling and the date 

such dismissal or ruling is upheld on appeal. 

By the Commission. 

April J. Tabor 

Secretary 

SEAL: 

ISSUED: